Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

To expand the ability of laboratories worldwide to assess the eligibility of patients with lung cancer for treatment with pembrolizumab, in a reliable and reproducible manner, we developed an assay that uses the 22C3 antibody concentrate on a widely available immunohistochemical autostainer, for both biopsy and cytology specimens.

Abstract

Pembrolizumab monotherapy has been approved for the first- and second-line treatment of patients with PD-L1-expressing advanced non-small cell lung cancer (NSCLC). Testing for PD-L1 expression with the PD-L1 immunohistochemistry (IHC) 22C3 companion diagnostic assay, which gives a tumor proportion score (TPS), has been validated on tumor tissue. We developed an optimized laboratory-developed test (LDT) that uses the 22C3 antibody (Ab) concentrate on a widely available IHC autostainer for biopsy and cytology specimens. The PD-L1 TPS was evaluated with 120 paired whole-tumor tissue sections and biopsy samples and with 70 paired biopsy and cytology samples (bronchial washes, n = 40; pleural effusions, n = 30). The 22C3 Ab concentrate-based LDT showed a high concordance rate between biopsy (~100%) and cytology (~95%) specimens when compared to PD-L1 IHC expression determined using the PD-L1 IHC 22C3 companion assay at both TPS cut points (≥1%, ≥50%). The optimized LDT presented here, using the 22C3 Ab concentrate to determine the PD-L1 expression in both tumor tissue and in cytology specimens, will expand the ability of laboratories worldwide to assess the eligibility of patients with NSCLC for treatment with pembrolizumab monotherapy in a reliable and reproducible manner.

Introduction

Recent clinical trials have demonstrated the efficacy of pembrolizumab, a humanized monoclonal IgG4 kappa isotype antibody that blocks the interaction between programmed cell death 1 (PD-1) and its ligands, PD-L1 and PD-L2, in the treatment of patients with advanced NSCLC1,2,3,4.

Currently, pembrolizumab is approved for treatment of PD-L1-expressing NSCLC in both treatment-naive patients with a PD-L1 expression TPS of ≥50% and no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) gen....

Protocol

All procedures have been approved by the local ethics committee (Human Research Ethics Committee, Centre Hospitalier Universitaire de Nice/Tumorothèque BB-0033-00025).

NOTE: This protocol is specifically adjusted for the use of the 22C3 antibody concentrate on a commercially available automated IHC stainer (referred to as autostainer here, see the Table of Materials) for tumor biopsies and cytology samples.

1. Preparation of Tumor Tissue Samples<.......

Representative Results

Using the procedure presented here, and as described in detail in this group's recent publications10,11, the optimized LDT was clinically validated with 120 archival FFPE NSCLC biopsy samples from patients who underwent surgical resection or a biopsy at the Pasteur University Hospital, Nice, between March 2007 and March 2016. Moreover, for the evaluation of PD-L1 expression of cytology samples, TPS was evaluated in 70 paired t.......

Discussion

We have validated an optimized LDT using the 22C3 PD-L1 antibody concentrate, by comparing it with the corresponding clinically validated commercial test10,11. The 22C3 concentrated antibody-based LDT showed a high concordance rate between biopsy (~100%) and cytology (~95%) specimens when compared to the PD-L1 IHC expression determined using the PD-L1 IHC 22C3 assay at both ≥1% TPS and the ≥50% TPS cut points. As recently recommended by the Internatio.......

Disclosures

The authors have nothing to disclose.

Acknowledgements

This study was sponsored by Merck & Co., Inc., Kenilworth, NJ, USA. The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

....

Materials

NameCompanyCatalog NumberComments
NovaPrep HQ1NovacytNAPreservative solution for cytology specimens
Novaprep® HQ+ BNovacytNAMucolytic solution
Tissue-Tek VIP 6Sakura6042 VIP 6
Tissue-Tek TEC 5 Tissue Embedding Console SystemSakura5229 TEC 5
microscope glass slide SuperFrost PlusThermo Fisher Scientific4951PLUS4
DL-Dithiothreitol powderSigma-AldrichD3801
Heidolph Multi Reax Vortex ShakerThermo Fisher Scientific13-889-410
Shandon CytoblockThermo Fisher Scientific7401150
22C3 anti-PD-L1 concentrate antibodyAgilent Dako#M365329
PD-L1 IHC 22C3 pharmDxAgilent DakoSK006
Autostainer Link 48Agilent DakoAS480
BenchMark ULTRA autostainerVentana#750-600
OptiView HQ Universal LinkerVentana#760-700
OptiView HRP MultimerVentana#760-700
OptiView Amplification H2O2Ventana#760-099
OptiView AmplifierVentana#760-099
OptiView Amplification MultimerVentana#760-100
OptiView DABVentana#760-700
OptiView CopperVentana#760-700
Hematoxylin IIVentana#790-2208
Bluing ReagentVentana#760-2037
Cell Conditioning 1 (CC1)Ventana#950-124
Tissue-Tek Film CoverslipperSakura4742

References

  1. Garon, E. B., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine. 372 (21), 2018-2028 (2015).
  2. Herbst, R. S., et al.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

22C3 AntibodyPD L1 ExpressionNon small Cell Lung CancerImmunotherapyTumor TissueCytology SpecimenBiopsyParaffin EmbeddingMicrotome SectioningBronchial WashingsCell Block PreparationAutostainerStaining Protocol

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved